The global CNS Treatment and Therapy Market is poised for substantial growth, with a projected valuation of USD 123.2 billion by the end of 2023. This market is expected to further expand at a CAGR of 5.2%, reaching USD 205.3 billion by 2033. The growth is driven by the increasing prevalence of neurological disorders and the continuous advancements in treatment options and therapies for central nervous system (CNS) diseases.
According to a recent study by Future Market Insights, degenerative diseases are leading the market, with an expected share of 31.7% in 2023. These diseases, including Alzheimer’s, Parkinson’s, and multiple sclerosis, are becoming more prevalent globally due to aging populations and other environmental and lifestyle factors. The growing focus on developing more effective therapies for these conditions is driving market expansion.
In addition to degenerative diseases, the market is also witnessing increased demand for innovative treatments for other CNS disorders such as depression, anxiety, and epilepsy. Technological advancements, such as the development of biologics, gene therapies, and precision medicine, are playing a key role in improving treatment outcomes and offering more personalized solutions for patients.
Key Takeaways:
- The CNS Treatment and Therapy Market is projected to grow at a CAGR of 5.2%, reaching USD 205.3 billion by 2033.
- Degenerative diseases will dominate the market, accounting for 31.7% of the market share in 2023.
- The rise in neurological disorders and the development of advanced treatment therapies are driving market growth.
- Innovations in biologics, gene therapies, and precision medicine are contributing to more effective and personalized CNS treatments.
As research and development continue to evolve, the CNS treatment and therapy market is positioned to offer new opportunities for enhancing patient care and addressing the growing global burden of neurological diseases.
Competitive Landscape
The various regional players operating in CNS therapeutics market adopt acquiring government funding to support novel research activities in the field of nervous system disorder diseases.
Global players with higher valuation incur higher spending on clinical trials of different products such as anesthetic anti-Parkinson drugs for launching it in market. Strategic collaborations is the major strategy adopted by such market players to expand their consumer base.
- Bingen expanded its business in China after getting approval from the National Medical Products Administration (NMPA) in 2021 for its popular drug dimethyl fumarate under the brand name TECFIDERA.
- To treat patients suffering from Alzheimer’s dementia the drug brexpiprazole is under development. After the successful completion of phase two trials Otsuka Pharmaceutical Co. Ltd. and Lundbeck pharmaceutical company continued its phase III clinical trials from April 2021.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the CNS treatment and therapy space, which are available in the full report.
Request a report sample to gain comprehensive insights: https://www.fmisamplereport.com/sample/rep-gb-14431
Key Companies Profiled
AbbVie Inc,; Alkermes Plc,; Allergan Plc,; AstraZeneca Plc,; BIAL Group,; Bristol-myers Squibb,; Eisai Co, Ltd.,; Endo Pharmaceuticals,; Eli Lilly and Co,; F. Hoffmann-La Roche Ltd.
Key Market Segments Covered in CNS Treatment and Therapy Industry Research
By Drug:
- Biologics
- Non Biologics
By Drug Class:
- Antidepressant
- Analgesics
- Immunomodulators
- Interferons
- Decarboxylase Inhibitors
- Others
By Disease:
- Neurovascular Disease
- Degenerative Disease
- Infectious Disease
- Mental Health
- Others
By Distribution Channel:
- Hospital Based Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
